

International Journal of Risk & Safety in Medicine 5 (1994) 223–225

THE INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE

Practical addenda

Addendum 1: Health authorities' ADE reporting forms

In the Western world, many health authorities have introduced a national form for the voluntary reporting of ADEs by health professionals. Over the course of the years, some of these forms have also undergone modifications; however, the type of information requested has largely remained unchanged. Such forms always constitute a trade-off between all the information that one would like to obtain on an ADE case and the amount one presumes doctors can provide without all too much additional effort. The UK authorities, for instance, seem to favour volume rather than content of ADE reporting (presumably on the premise that cases can be followed up retrospectively if there appears to be a problem), whereas the USA form is more detailed.

REPORT ON SUSPECTED ADVERSI			dverse Reactions to Drugs section of BNF)			
	AMES					
DATE OF BIRTH (OR AGE)	SEX: M	JF	F WEIGHT (kg)			
ospital if relevant Hospital NumberConsultant in charge/GP Principal_						
SUSPECTED DRUG (Give brand nai known)	•	r if	ROUTE DAILY DOSE			
DATE STARTED DATE STOPPED			THERAPEUTIC INDICATION			
SUSPECTED REACTIONS			REPORTING DOCTOR			
	0.00	-	Name			
DATE REACTION STARTED D		_				
SEND TO CSM, FREEPOST, London SW8 5BR OR if you are in one of the following NHS regions: TO CSM Mersey, FREEPOST, Liverpool L3 3AB			TelephoneSpecialty Signature Date			
OR CSM West Midlands, FREEPOST, OR CSM Northern, FREEPOST 1085, OR CSM Wales, FREEPOST, Cardiff (Newcastle upon Tyne NE1 18	R	If you would like information about other reports associated with the suspected drug, tick here			

Fig. 1. The UK reporting form.

0924-6479/94/\$07.00 © 1994 Elsevier Science B.V. All rights reserved SSDI 0924-6479(94)00029-6

This Addendum gives the following two examples:

— The UK form (Fig. 1), widely known as "the yellow card". The UK was the first country to introduce this type of form. At present, it is made available to

11//		TARY reporting	Form Api FDA Use Only	proved: OMB No. 0910-0291 Expires:12/31/94 See OMB statement on reverse	
		sionals of adverse		Triage unit	
MILLYVAICE	events and pr	oduct problems	sequence #		
THE FDA MEDICAL PRODUCTS REPORTING PROGRA	Page	_ of			
A. Patient information	1 1 1 1 1 1 W	C. Suspect me	dication(s)		
Patient identifier 2. Age at time	3. Sex 4. Weight		rength & mfr/labeler, if known)		
of event:	female lbs	#1			
Date	male or	#2			
In confidence of birth:	kgs	2. Dose, frequency & ro	ute used 3. Therapy d	ates (if unknown, give duration)	
B. Adverse event or product probl		#1	from to (or bes	t estimate)	
	n (e.g., defects/malfunctions)	"			
Outcomes attributed to adverse event (check all that apply) disability disability	/	#2	#2		
	tal anomaly	Diagnosis for use (incl. #1	dication)	Event abated after use stopped or dose reduced	
Ife-threatening required permant	I intervention to prevent ent impairment/damage	# i		#1 yes no doesn'	
hospitalization – initial or prolonged other:		#2			
3. Date of 4. Date of		6. Lot # (if known)	7. Exp. date (if known)	#2yesnodoesn'i	
event this report (mordaylyr) (mordaylyr)	t	#1	#1	Event reappeared after reintroduction	
5. Describe event or problem		#2	#2	1	
		9. NDC # (for product pro	blems only)	#1 yes no doesn't	
		-	-	#2 yes no doesn'	
		10. Concomitant medical	al products and therapy dates	(exclude treatment of event)	
		D. Suspect me	edical device		
		2. Type of device			
		3. Manufacturer name &	address	4. Operator of device	
				health professional	
				lay user/patient	
				other:	
		6		5. Expiration date	
		model #			
6. Relevant tests/laboratory data, including dates	catalog #		7. If implanted, give date		
				(mo/day/yr)	
		serial #		8. If explanted, give date	
		lot #		(mo/day/yr)	
		other #			
		9. Device available for e		end to FDA)	
		yes n		(mo/day/yr)	
		10. Concomitant medica	al products and therapy dates	(exclude treatment of event)	
7. Other relevant history, including preexisting medica	conditions (e.g., allergies,				
race, pregnancy, smoking and alcohol use, hepatic/rena					
			e confidentiality section	on on back)	
•		Name, address & ph	ione #		
		2. Health professional?	3. Occupation	4. Also reported to	
	OT 54V.	yes no	,	manufacturer	
Mail to: MEDWATCH 5600 Fishers Lane	or FAX to: 1-800-FDA-0178		your identity disclosed to	user facility	
Rockville, MD 20852-97	87	the manufacturer, p	ace an " X " in this box.	distributor	

Fig. 2. The USA reporting form.

doctors via vehicles such as the BNF (British National Formulary), the Data Sheet Compendium and prescription pads. Many countries copied at least the yellow colour of the British form when they introduced their own national "brand".

— The FDA form whose lay-out was recently (1993) significantly revised to also encompass adverse effects of medical products other than medicines. This revised form has been intensively advertised in the context of a targeted "MedWatch" programme and also carries "MedWatch" at the top.